Faculty News
In Memoriam: Isaiah Fidler, D.V.M, Ph.D.
The Center for Cancer Research mourns the recent death of past colleague and friend Isaiah Fidler, D.V.M., Ph.D. He joined the National Cancer Institute in 1975 and led the metastasis program at the Frederick Cancer Research Facility. His eight years at NCI produced some of his early innovative work in unraveling the riddles of how cancer spreads.
Read MoreIn Memoriam: Stephen Oroszlan, Ph.D.
The Center for Cancer Research mourns the recent death of past colleague and friend Stephen Oroszlan. He was an esteemed member of the NCI community from 1976-1995 and served as a Scientist Emeritus since 1995.
Read MoreEytan Ruppin quoted in New York Times story on treating COVID-19
The New York Times has reported on a new paper detailing drugs with the potential to treat COVID-19 by researchers from international institutions. Eytan Ruppin, Ph.D., Chief of the Cancer Data Science Laboratory, turned the computer network his lab uses toward analyzing some of the drugs that did best in the screening to predict which are likely to succeed in actual patients and in what combinations.
Read MoreIra Pastan selected as a 2020 Sammies finalist
Ira Pastan, M.D., Co-Chief of the Laboratory of Molecular Biology, has been selected as one of 27 Samuel J. Heyman Service to America Medal (Sammies) finalists. These finalists are outstanding federal employees who serve the public good and are addressing many of our country’s greatest challenges. Dr. Pastan is nominated for discovering a new class of drugs that can successfully treat a rare form of leukemia and hold promise to be effective therapies for pancreatic and lung cancer as well as mesothelioma.
Read MoreJohn Schiller elected to the National Academy of Sciences
John T. Schiller, Ph.D., Deputy Chief of the Laboratory of Cellular Oncology, has been elected to the National Academy of Sciences for his distinguished and continuing achievements in original research. Dr. Schiller, in close partnership with Dr. Doug Lowy, has made fundamental contributions to our understanding of human papillomavirus (HPV) culminating in the development of the prophylactic vaccines Cervarix and Gardasil, which protect from HPV-related cancers, including cervical cancer.
Read MoreAndrea Apolo receives Arthur S. Flemming Award
Andrea B. Apolo, M.D., NIH Lasker Clinical Research Scholar in the Genitourinary Malignancies Branch, is a recipient of this year’s Arthur S. Flemming Award, which honors the accomplishments of mid-career federal employees. Dr. Apolo received the award for her work leading a clinical trial demonstrating that avelumab treatment led to prolonged survival in patients with refractory metastatic urothelial carcinoma. She then led the effort to get avelumab approved by the FDA for the treatment of bladder cancer.
Read MoreDr. William Dahut discusses coronavirus and cancer patients on Frankly Speaking about Cancer podcast
William L. Dahut, M.D., CCR Clinical Director, was a guest on the Frankly Speaking about Cancer podcast for their spotlight on coronavirus series. He addressed concerns from cancer patients and their caregivers and shared advice on what cancer patients can do to stay safe.
Read MoreIn Memoriam: Nancy Colburn, Ph.D.
The Center for Cancer Research mourns the recent death of past colleague and friend Nancy Colburn, Ph.D. She was an esteemed member of the NCI community for 36 years from 1976-2012.
Read MoreChristian Hinrichs and Steve Rosenberg receive Federal Laboratory Consortium award
Christian Hinrichs, M.D., Investigator in the Experimental Transplantation and Immunotherapy Branch, and Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, received an award from the Federal Laboratory Consortium for Technology Transfer (FLC) for their project, “New, First-in-class Immunotherapy for Treatment of Recurrent, Metastatic Cervical Cancer.” This award recognizes employees of FLC member laboratories and non-laboratory staff who have accomplished outstanding work in the process of transferring federally developed technology.
Read MoreUdo Rudloff and team develop potential new type of immunotherapy
New research led by Udo Rudloff, M.D., Ph.D., Investigator in the Pediatric Oncology Branch, describes a potential new type of immunotherapy that applies across many types of cancer. The findings were reported in Science Translational Medicine and showed this approach has potential for treating other diseases as well. This work was featured in a recent press release from the National Center for Advancing Translational Sciences.
Read More